维普中文期刊产品整合服务
8篇 您的检索式:作者名="Hans Wedel"
    题名 作者 年代 出处 被引量
1Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction: Long-Term Results From the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarctio显示文摘Klas Malmberg Anna Norhammar Hans Wedel Lars Ryden 1999Circulation1999,,20:1
2Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year显示文摘Klas Malmberg Lars Rydén Suad Efendic Johan Herlitz Peter Nicol Anders Waldenstrom Hans Wedel Lennart Welin 1995Journal of the American College of Cardiology1995,,1:1
3Can the relation between tooth loss and chronic disease be explained by socio-economic status? A 24-year follow-up from the Population Study of Women in Gothenburg, Sweden显示文摘Claudia Cabrera Magnus Hakeberg Margareta Ahlqwist Hans Wedel Cecilia Bj?rkelund Calle Bengtsson Lauren Lissner 2005European Journal of Epidemiology2005,,3:1
4Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial Infarction 显示文摘 Anna Norhammar Hans Wedel 1999Circulation1999,99,:1
5Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomise显示文摘Peter S Sever Bj?rn Dahl?f Neil R Poulter Hans Wedel Gareth Beevers Mark Caulfield Rory Collins Sverre E Kjeldsen Arni Kristinsson Gordon T McInnes Jesper Mehlsen Markku Nieminen Eoin O’Brien Jan ?stergren 2003The Lancet2003,,9364:1
6Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension显示文摘Neil Chapman Joanna Dobson Sarah Wilson Bj?rn Dahl?f Peter S. Sever Hans Wedel Neil R. Poulter 2007Hypertension2007,,4:1
7Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis显示文摘Dipak Kotecha Jane Holmes Henry Krum Douglas G Altman Luis Manzano John G F Cleland Gregory Y H Lip Andrew J S Coats Bert Andersson Paulus Kirchhof Thomas G von Lueder Hans Wedel Giuseppe Rosano Marcelo C Shibata Alan Rigby Marcus D Flather 20142014 (9961)2014,,9961:1
8抗高血压治疗期间心电图左心室肥厚消退及其对主要心血管事件的预测作用显示文摘背景:心电图左心室肥厚(left ventficular hypertophy,LVH)是心血管并发症及死亡的强预测指标。然而,在抗高血压治疗期间心电图LVH程度变化的预测价值仍不清楚。 目的:验证抗高血压治疗期间心电图LVH程度越轻,心血管并发症与死亡率越低,并与血压水平及其降低和治疗方式无关的假说。 设计、设置及参试者:1995~2001年于9193例55至80岁(均值,67岁)男性和女性高血压患者进行的双盲、随机、平行组研究。心电图LVH用康奈尔电压一时间乘积或Sokolow—Lyon电压表示,患者均入选氯沙坦降低高血压终点事件干预研究(Losartan Intervention For Endpoint,LIFE)。 干预:以氯沙坦或阿替洛尔为基础的治疗方案,随访评估至少4年(均值,4.8年[SD,0.9])。主要结果测定:心血管死亡、心肌梗死或卒中复合终点与基线及随后1年或每年心电图LVH严重程度的关系。 结果:1096例(11.9%)发生心血管死亡、非致死性心肌梗死或卒中。在控制治疗方式、基线Framingham危险记分、基线和治疗期间血压以及基线心电图LVH严重程度(康奈尔乘积或Sokolow—Lyon电压)的Cox回归模型中,康奈尔乘积和Sokolow—Lyon电压所示治疗中LVH严重程度较低者,复合心血管终点事件的发生率分别降低14%和17%(康奈尔乘积每降低1050mm×ms,[1-SD]:校正风险比[hazard ratio,HR],0.86;95%可信区间[confidence interval,CI],0.82~0.92;P〈0.001;Sokolow—Lyon电压每降低10.5mm[1-SD]:HR,0.83;95%CI,0.78~0.88;P〈0.01)。在平行分析中,较低的康奈尔乘积和Sokolow—Lyon电压均与较低的心血管死亡(分别为HR,0.78;95%CI,0.73~0.83;P〈0.001和HR,0.80;95%CI,0.73~0.87;P〈0.001)、心肌梗死(HR,0.90;95%CI,0.82~0.98;P=0.01和HR,0.90;95%CI,0.81~1.00;P=0.04))和卒中(HR,0.90;95%CI,0.84~0.96;P=0.002;HR,0.81;95%CI,0.75~0.89;P〈0.001)独立相关。 结论:抗高血压治疗期间,根据康奈尔乘积和Sokolow—Lyon电压判定的心电图LVH程度较轻与心血管并发症和死亡可能性较低相关,而且独立于原发性高血压患者的血压降低及治疗方式。旨在改善或预防心电图LVH的抗高血压治疗可以改善患者的预后。Peter M. Okin, MD Richard B. Devereux, MD Sverker Jern, MD Sverre E. Kjedsen, MD,PhD Stevo Julius, MD, ScD Markkus S. Nieminen, MD, PhD Steven Snapinn, PhD Katherine E. Harris, DrPH Peter Aurup, MD Jonathan M. Edelman, MD Hans Wedel, PhD Lars H. Lindholm, MD, PhD Bjorn Dahlof MD, PhD 倪靖炜(译) 沈卫峰(校) 2005美国医学会杂志(中文版)2005,24,6:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费